©2022 Australasian Society of Clinical Immunology and Allergy (ASCIA)
ABN 45 615 521 452


Position Statement - COVID-19 Prophylaxis in People with Immune Deficiencies

5 May 2022

pdfASCIA HP COVID-19 Prophylaxis Immune Deficiency Position Statement 2022152.19 KB

The National (Australian) COVID-19 Clinical Evidence Taskforce (the Taskforce), has issued recommendations on the use of monoclonal antibodies tixagevimab plus cilgavimab (Evusheld) for COVID-19 prevention (prophylaxis). Evusheld is supplied by Astra Zeneca, and has provisional approval in Australia from the Therapeutic Goods Administration (TGA) since January 2022:

Product information is available at which includes the following details:

Supply of Evusheld is currently limited, and is only available in Australia from the National Stockpile. Therefore Evusheld can only be considered for pre-exposure prophylaxis in exceptional circumstances, in people who are severely immunocompromised and at high risk of progression to severe COVID-19.

This includes people who are expected to have an inadequate response to vaccination, who have:

ASCIA recommends that allocation of Evusheld should be based on the severity of the underlying immune deficiency, the risk of acquiring coronavirus infection, and the risk of severe COVID, supported by the patient’s specialist recommendation. It is noted that there is currently no clinical data regarding effectiveness of Evusheld specific to SARS-CoV-2 variants of concern.

The Taskforce recommendations on Evusheld for prophylaxis are available at:

© ASCIA 2022

ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand. ASCIA resources are based on published literature and expert review, however, they are not intended to replace medical advice. The content of ASCIA resources is not influenced by any commercial organisations. For more information go to

To donate to immunology/allergy research go to